226 related articles for article (PubMed ID: 23018874)
1. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
2. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.
Krohn A; Freudenthaler F; Harasimowicz S; Kluth M; Fuchs S; Burkhardt L; Stahl P; C Tsourlakis M; Bauer M; Tennstedt P; Graefen M; Steurer S; Sirma H; Sauter G; Schlomm T; Simon R; Minner S
Mod Pathol; 2014 Dec; 27(12):1612-20. PubMed ID: 24762546
[TBL] [Abstract][Full Text] [Related]
5. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
6. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
Guo CC; Wang Y; Xiao L; Troncoso P; Czerniak BA
Hum Pathol; 2012 May; 43(5):644-9. PubMed ID: 21937078
[TBL] [Abstract][Full Text] [Related]
7. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
8. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
9. MAGI-2 in prostate cancer: an immunohistochemical study.
Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.
Kluth M; Meyer D; Krohn A; Freudenthaler F; Bauer M; Salomon G; Heinzer H; Michl U; Steurer S; Simon R; Sauter G; Schlomm T; Minner S
Oncotarget; 2016 Jan; 7(4):3897-904. PubMed ID: 26684029
[TBL] [Abstract][Full Text] [Related]
11. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB
Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708
[TBL] [Abstract][Full Text] [Related]
13. Single-cell genetic analysis reveals insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis.
Heselmeyer-Haddad KM; Berroa Garcia LY; Bradley A; Hernandez L; Hu Y; Habermann JK; Dumke C; Thorns C; Perner S; Pestova E; Burke C; Chowdhury SA; Schwartz R; Schäffer AA; Paris PL; Ried T
Am J Pathol; 2014 Oct; 184(10):2671-86. PubMed ID: 25131421
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features.
Fine SW; Gopalan A; Leversha MA; Al-Ahmadie HA; Tickoo SK; Zhou Q; Satagopan JM; Scardino PT; Gerald WL; Reuter VE
Mod Pathol; 2010 Oct; 23(10):1325-33. PubMed ID: 20562851
[TBL] [Abstract][Full Text] [Related]
15. Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.
Fallahabadi ZR; Noori Daloii MR; Mahdian R; Behjati F; Shokrgozar MA; Abolhasani M; Asgari M; Shahrokh H
Gene; 2016 Jan; 575(2 Pt 3):755-60. PubMed ID: 26424596
[TBL] [Abstract][Full Text] [Related]
16. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
17. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
18. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.
Morais CL; Guedes LB; Hicks J; Baras AS; De Marzo AM; Lotan TL
Hum Pathol; 2016 Sep; 55():117-25. PubMed ID: 27189342
[TBL] [Abstract][Full Text] [Related]
19. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.
Krohn A; Diedler T; Burkhardt L; Mayer PS; De Silva C; Meyer-Kornblum M; Kötschau D; Tennstedt P; Huang J; Gerhäuser C; Mader M; Kurtz S; Sirma H; Saad F; Steuber T; Graefen M; Plass C; Sauter G; Simon R; Minner S; Schlomm T
Am J Pathol; 2012 Aug; 181(2):401-12. PubMed ID: 22705054
[TBL] [Abstract][Full Text] [Related]
20. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
